Navigation Links
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
Date:7/27/2009

- Management to discuss second quarter financial results -

LAVAL, QC, July 27 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 7, 2009 at 8:30 a.m. (ET) to discuss its second quarter 2009 financial results. Labopharm will report its second quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labophar
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
2. Labopharm amends debt facility agreement with Hercules
3. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
4. Labopharm Reports Results for First Quarter Fiscal 2009
5. Labopharm announces details for first quarter results conference call and annual meeting
6. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
7. Labopharm to present at Cowen 29th Annual Health Care Conference
8. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
9. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
10. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
11. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... Visitors to our region recognize how ... ensure its protection. Bob Kiesendahl, one of the owners ... Delaware Highlands Conservancy for donations collected through participation in ... add up fast, as visitors welcome the opportunity to ... Region. , The Kiesendahl family has owned Woodloch Resort ...
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service ... features an Instant Quote tool on its website, LTCconsumer.com ... Consumer. Quotes are free and unlimited. , The Instant ... areas – including age, gender, and state of residence – ... don’t need to enter any contact information to get started). ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The Institute ... is pleased to announce that Arianna Huffington has joined as ... of the Health Coach Training Program . , Arianna ... Post, a world-renowned news and blogging site that won a ... author of fourteen books and was included on the Forbes ...
Breaking Medicine News(10 mins):Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3
... , WESTMINSTER, Colo., Dec. 7 ... change to the Noise Reduction Rating (NRR) for hearing protection ... recommendations to the United States Environmental Protection Agency (EPA). Based ... to improve the utility of hearing protection devices for occupational ...
... Advisory articles are posted on the ... 7 All Pennsylvania registered nurses can receive continuing education hours ... that are posted on the Pennsylvania State Nurses Association (PSNA) web ... to have 30 hours of continuing education every two years for ...
... a history of delinquency in childhood are more likely to die ... just from the obvious consequences of antisocial behaviour, new research indicates. ... the Journal of Public Health , is the first to ... as parental factors, affect various health outcomes 40 years later. ...
... ... experienced dentist is a crucial step in preserving your smile and dental health. , ... Minneapolis, MN (PRWEB) December 7, 2009 ... and inconvenience of emergency dental procedures. Whether a tooth is cracked, loosened, or knocked out, ...
... more complicated testing, expert says, , MONDAY, Dec. 7 (HealthDay ... detect whether a child has obstructive sleep apnea, U.S. researchers ... costly and inconvenient sleep studies in children who snore, only ... or obstructive sleep apnea, Dr. David Gozal, a professor and ...
... , ATLANTA, ... antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting ... patients with partial-onset seizures. Results of presented research demonstrate ... up to three years, and a consistent long-term tolerability profile. ...
Cached Medicine News:Health News:NHCA Recommendations to EPA on NRR Change Intend to Improve Utility of Hearing Protection Devices at Work and at Home 2Health News:NHCA Recommendations to EPA on NRR Change Intend to Improve Utility of Hearing Protection Devices at Work and at Home 3Health News:PA Registered Nurses Can Earn Continuing Education Hours Through Pennsylvania Patient Safety Advisories 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 3Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:Urine Sample May Reveal Sleep Disorder in Kids 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
The Perfect Vac Quad Manifold allows one to four 96-well plates to be processed simultaneously. A single plate may be processed in 30 minutes; four plates are processed in 45 minutes....
... and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim with over ... ... ... ...
... The TurboVap Concentration Workstations from Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down ... use around the world today. ... ... ...
Medicine Products: